Early trial explores new drug for blood cancers in japanese patients

NCT ID NCT05673460

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called nemtabrutinib in 7 Japanese adults with certain blood cancers (like chronic lymphocytic leukemia). The main goals were to check the drug's safety and how the body processes it. Researchers looked for side effects and measured drug levels in the blood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia lymphoplasmacytic lymphoma neoplasm of mature B-cells Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MATURE B-CELL NEOPLASMS

Contacts and locations

Locations

Chiba Cancer Center ( Site 0005)

Chiba, 260-8717, Japan
Kindai University Hospital ( Site 0006)

Sayama, Osaka, 589-8511, Japan
Kyushu University Hospital ( Site 0008)

Fukuoka, 812-8582, Japan
Nagoya University Hospital ( Site 0003)

Nagoya, Aichi-ken, 466-8560, Japan
National Cancer Center Hospital East ( Site 0002)

Kashiwa, Chiba, 2778577, Japan
Okayama University Hospital ( Site 0007)

Okayama, 700-8558, Japan
Yamagata University Hospital ( Site 0001)

Yamagata, 990-9585, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.